Supriya Lifescience Limited has announced that the board, at its meeting held on Friday, November 6, 2026, approved the appointment of Mangesh Vaze as Chief Operating Officer and Senior Management Personnel of the company, effective from November 6, 2026. The decision followed a recommendation from the Nomination and Remuneration Committee and reflects the board’s intent to strengthen the company’s operational leadership as it advances its manufacturing agenda.
Mangesh Vaze brings a robust 34-year track record in production, process engineering, API manufacturing and overall operations. He holds a BE in Chemical Engineering and an Executive MBA with a focus on strategy and finance. Over the course of his career, he has been associated with leading Indian pharmaceutical groups, including Zydus Lifesciences Ltd., Cipla Ltd., Mylan Laboratories Ltd., Apotex Pharmachem India Pvt Ltd, Wockhardt Ltd., Orchid Chemicals & Pharmaceuticals Ltd., and Lupin Ltd., where he has shouldered responsibilities across manufacturing and operations settings. His appointment is positioned to infuse deep technical and strategic insight into Supriya Lifescience’s manufacturing footprint.
Industry observers will be watching how the new COO leverages his extensive experience to drive efficiencies, scale production, and fortify export capabilities as the company continues to pursue growth in a competitive global health landscape. The company notes that Mr. Vaze’s role as Senior Management Personnel aligns with its ongoing focus on strengthening leadership at the highest levels of operations while maintaining momentum on its key business priorities.